Citius Pharmaceuticals Inc (CTXR)
Citius Pharmaceuticals, Inc. is a biopharmaceutical company listed on NASDAQ under the ticker CTXR. The company develops and seeks to commercialize products focused on critical care and related medical needs. Its approved product, LYMPHIR, is a targeted immunotherapy used in cutaneous T-cell lymphoma. Citius also has several late-stage development programs, including Mino-Lok for catheter-related bloodstream infections, Halo-Lido for hemorrhoid symptom relief, and NoveCite for acute respiratory distress syndrome. Founded in 2007, the company is headquartered in Cranford, New Jersey.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CTXR
|
$0.64
|
20.3% Upside
|
Undervalued
|
$4
|
656.1% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-0.3x
|
0.2x
|
2.4x
|
13.194 M
|
16.955 M
|
3.7%
|
98.2%
|
-17.7
|
—
|
68.4%
|
